Empagliflozin was found to be associated with a lower combined risk for cardiovascular death or hospitalization for heart failure compared with placebo in patients receiving recommended therapy for heart failure.
Patients with HFpEF have substantial exercise intolerance, which may be due to peripheral factors.
A 4-step protocol was found to accurately and efficiently identify patients with STEMI who can be safely discharged after successful primary PCI.
Quality of care and in-hospital mortality were found to be comparable for patients with heart failure who were covered by Medicare Advantage or fee-for-service Medicare.
In a European study, approximately one-third of hospitalizations involving patients with recurrent hyperkalemia directly related to serum potassium elevation.
Supplementation with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) is associated with a reduced risk for myocardial infarction (MI) and coronary heart disease (CHD) events.
Clinical outcomes of patients with heart failure were found to correlate with alterations in the levels of a set of biomarkers.
Coronary microvascular dysfunction was found to be independently associated with hospitalization for heart failure and cardiovascular death in patients with chronic stable HFpEF.
Having a nonpsychotic mental disorder in adolescence is associated with increased risk of subsequent myocardial infarction, with stress resilience partially attenuating the association.
Secondary results from the DAPA-HF trial suggest the sodium-glucose cotransporter 2 inhibitor may enable use of mineralocorticoid receptor antagonists in some patients with heart failure.
